Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 1/20 | 0.51 |
| ▸ | SSTR5 | P35346 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.48 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | PLK1 | P53350 | 1/20 | 0.48 |
| ▸ | IGF1R | P08069 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3933554 | 0.93 | SSTR5 (0.47) | SSTR4SSTR5ALDH1A1HPGDRAB9A | |
| SCHEMBL3537704 | 0.93 | SSTR5 (0.47) | SSTR4SSTR5ALDH1A1HPGDRAB9A | |
| SCHEMBL17034326 | 0.90 | HTR4 (0.51) | SLC6A5BRD4 | |
| SCHEMBL13575476 | 0.90 | SSTR5 (0.55) | SSTR5ALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL28079636 | 0.89 | HPGD (0.62) | SSTR5ALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL13175554 | 0.88 | HRH3 (0.55) | SSTR5ALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL738237 | 0.87 | HTR4 (0.53) | BRD4 | |
| SCHEMBL9996770 | 0.86 | SSTR4 (0.51) | SSTR4ALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL13575620 | 0.85 | HPGD (0.51) | SSTR5ALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL13575616 | 0.85 | BRD4 (0.53) | SSTR5ALDH1A1HPGDRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50082-E1 | (5,6-dihydro)pyrimido[4,5-e]indolizines | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2024-08-20 | — | — | US | disclosed |
| EP-3129374-B1 | (5,6-DIHYDRO)PYRIMIDO[4,5-E]INDOLIZINES | NETHERLANDS TRANSLATIONAL RES CENTER B V (NL) | 2018-12-19 | — | — | EP | disclosed |
| US-9856258-B2 | (5,6-dihydro)pyrimido[4,5-E]indolizines | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2018-01-02 | — | — | US | disclosed |
| US-20170096432-A1 | (5,6-DIHYDRO)PYRIMIDO[4,5-E]INDOLIZINES | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2017-04-06 | — | — | US | disclosed |
| EP-3129374-A1 | (5,6-DIHYDRO)PYRIMIDO[4,5-E]INDOLIZINES | Netherlands Translational Research Center B.V. (NL) | 2017-02-15 | — | — | EP | disclosed |
| WO-2015155042-A1 | (5,6-DIHYDRO)PYRIMIDO[4,5-E]INDOLIZINES | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2015-10-15 | — | — | WO | disclosed |
| EP-2564850-A1 | Polo-like kinase inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2013-03-06 | — | — | EP | disclosed |
| WO-2011036566-A1 | METHODS FOR PREPARING PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-31 | — | — | WO | disclosed |
| EP-1983987-B1 | DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009153197-A1 | HALO-SUBSTITUTED PYRIMIDODIAZEPINES AS PLKL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-23 | — | — | WO | disclosed |
| US-20090312336-A1 | DIHYDROPTERIDINE COMPOUNDS AS ANTI PROLIFERATIVE AGENTS | ASTRAZENECA AB (SE) | 2009-12-17 | — | — | US | disclosed |
| US-20090312336-A1 | DIHYDROPTERIDINE COMPOUNDS AS ANTI PROLIFERATIVE AGENTS | ASTRAZENECA AB (SE) | 2009-12-17 | — | — | US | disclosed |
| US-20090312336-A1 | DIHYDROPTERIDINE COMPOUNDS AS ANTI PROLIFERATIVE AGENTS | ASTRAZENECA AB (SE) | 2009-12-17 | — | — | US | disclosed |
| WO-2009112524-A1 | PYRIDOPYRIMIDINES AS PLK1 ( POLO-LIKE KINASE) INHIBITORS | 4SC AG (DE) | 2009-09-17 | — | — | WO | disclosed |
| EP-2100894-A1 | Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors | 4SC AG (DE) | 2009-09-16 | — | — | EP | disclosed |
| WO-2009042711-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-02 | — | — | WO | disclosed |
| WO-2007135374-A1 | DIHYDROPTERIDINE COMPOUNDS AS ANTI PROLIFERATIVE AGENTS | ASTRAZENECA AB (SE) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007095188-A2 | DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096432-A1 | (5,6-DIHYDRO)PYRIMIDO[4,5-E]INDOLIZINES | DHFR, CYP2D6, DPYD | SSTR4 1266/4885SSTR5 358/4885ALDH1A1 111/4885 |
| US-20090312336-A1 | DIHYDROPTERIDINE COMPOUNDS AS ANTI PROLIFERATIVE AGENTS | QDPR, PLK2, PFKP | SSTR4 520/4885SSTR5 717/4885ALDH1A1 921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.